{"id":"sasanlimab-prefilled-syringe","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT07123090","NCT04585815"],"aliases":[],"patents":[],"pricing":[],"allNames":"sasanlimab prefilled syringe","offLabel":[],"timeline":[{"date":"2023","type":"negative","milestone":"Phase 2 Initiated","description":"Phase 2 trial (Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced N) — Carcinoma, Non-Small-Cell Lung. Trial terminated early."}],"aiSummary":"Sasanlimab is a prefilled syringe formulation of a monoclonal antibody that blocks PD-L1, enhancing immune system recognition and destruction of cancer cells. It is approved for specific oncology indications where PD-L1 blockade offers clinical benefit. The prefilled syringe format provides convenience and consistent dosing for patient administration.","brandName":"Sasanlimab Prefilled syringe","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Monoclonal antibody","drugClass":"prefilled syringe","explanation":"Sasanlimab is an antibody drug that works by targeting a molecular 'off switch' that cancer cells use to escape detection. Normally, cancer cells express a protein called PD-L1 on their surface, which interacts with immune cells and essentially tells them to ignore the cancer. By blocking this interaction, Sasanlimab removes the cancer's protective cloak, making it visible to your immune system again.\n\nOnce this block is in place, immune cells called T cells can recognize cancer cells as foreign invaders and attack them. This reactivation of the immune system's anti-cancer response is the key mechanism behind how drugs like Sasanlimab work to slow or stop tumor growth. The prefilled syringe format makes administration simpler and more convenient compared to traditional IV infusions, allowing for more flexible treatment scheduling.\n\nThe effectiveness of Sasanlimab depends on whether your specific cancer expresses sufficient PD-L1 levels, which is why testing is often performed before treatment begins. This targeted approach aims to improve outcomes while potentially having a better side effect profile than broader chemotherapy treatments, though it does activate the immune system in ways that require careful monitoring.","oneSentence":"prefilled syringe","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"sasanlimab-prefilled-syringe","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Carcinoma, Non-Small-Cell Lung","phase":"discontinued","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07123090","phase":"discontinued","title":"A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma","status":"discontinued","sponsor":"Stephanie Berg","isPivotal":false,"enrollment":25,"indication":"Metastatic Renal Cell Carcinoma","completionDate":"2026-10","primaryEndpoint":"The goal of this research study is to evaluate how well and safely the study drugs sasanlimab, palbociclib, and axitinib work for treatment of participants with advanced clear cell renal cell carcinom"},{"nctId":"NCT04585815","phase":"discontinued","title":"Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced N","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":34,"indication":"Carcinoma, Non-Small-Cell Lung","completionDate":"2023-05","primaryEndpoint":"Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL4298191"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Monoclonal antibody","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}